Ocular Therapeutix Inc (NASDAQ:OCUL) currently has a daily average trading volume of 1.09M but it saw 1588940 shares traded in last market. With a market cap of 1.55B USD, the company’s current market price of $9.92 came falling about -6.42 while comparing to the previous closing price of $10.60. In past 52 weeks, the stock remained buoying in the range of price level as high as $11.77 and as low as $2.05. In the recent trading on the day, stock has struck highest price mark of $9.82 while lowest mark touched by it was $10.735.
Taking a look at 20-day trading activity of Ocular Therapeutix Inc (OCUL) gives us an average price of $10.86, while its current price level is -15.75% below from 52-week high level whereas it is 383.90% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $9.86 while that of 200 days or SMA-200 reads an average of $8.01. A closer look into the stock’s movement over the week reveals that its volatility is standing at 5.79% during that period while stretching the period over a month that decreases to 4.77%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 42.29 which implies that the stock is in neutral territory.
TD Cowen upgraded its recommendation for the stock as a “Buy” from “Hold” on June 20, 2024 while assigning a price target range of $7-$11. Piper Sandler issued its recommendations for the stock as it resumed the price target for the stock is $15.
Over the week, OCUL’s stock price is moving -7.98% down while it is -13.51% when we observe its performance for the past one month. Year-to-date it is 122.42% up and over the past year, the stock is showing an upside performance of 350.91%.
Currently, Ocular Therapeutix Inc’s total number of outstanding shares is 155.92M. Company’s return on investment (ROI) stands at -30.68% and return on equity (ROE) at -72.67%. Stock’s beta reads 1.21. Stock has a price to book (P/B) ratio of 4.09 while price to sale or P/S ratio amounts to 25.31. Its return on asset (ROA) is -43.26% on average.
